MTOR and neoplasm: AKT2, a key player in the PI3K/AKT/mTOR signaling pathway, is frequently dysregulated in cancers (Attoub et al., 2022), promoting tumor growth and therapeutic resistance (Chau and Ashcroft, 2004; Riggio et al., 2017; Rychahou et al., 2008; Su et al., 2021) The strong binding of complex 9 to AKT2 suggests its potential to disrupt this pathway, thereby inhibiting tumor proliferation.